Clinical Trials Directory

Trials / Completed

CompletedNCT04519788

AT-301 Nasal Spray in Healthy Adults

A Double-blinded, Randomised, and Placebo-controlled Safety Study of AT-301 Nasal Spray in Healthy Adults

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Atossa Therapeutics, Inc. · Industry
Sex
All
Age
18 Years – 64 Years
Healthy volunteers
Accepted

Summary

This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The study will be conducted in 2 parts: a single ascending dose (SAD) part (Part 1) followed by a multiple ascending dose (MAD) part (Part 2).

Conditions

Interventions

TypeNameDescription
DRUGAT-301BNasal Spray
DRUGAT-301ANasal Spray

Timeline

Start date
2020-08-07
Primary completion
2020-12-08
Completion
2021-01-12
First posted
2020-08-20
Last updated
2021-01-19

Locations

1 site across 1 country: Australia

Regulatory

Source: ClinicalTrials.gov record NCT04519788. Inclusion in this directory is not an endorsement.